Seminars in Nephrology
Volume 30, Issue 1 , Pages 51-58 , January 2010

Metabolic Syndrome and Mild to Moderate Chronic Kidney Disease Among Minorities

  • Sankar D. Navaneethan, MD, MPH

      Affiliations

    • Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
    • Corresponding Author InformationAddress reprint requests to Sankar D. Navaneethan, MD, MPH, Department of Nephrology and Hypertension/Q7-155, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195
    • ,
  • Jesse D. Schold, PhD

      Affiliations

    • Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute and the Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
    • ,
  • Titte R. Srinivas, MD

      Affiliations

    • Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

References 

  1. United States Renal Data System. http://www.usrds.org/2009/pdf/V2_02_INC_PREV_09.PDF[accessed 2009 October 28]
  2. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14:2902–2907
  3. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68:914–924
  4. National Institute of Health. Third Report of the National Cholesterol Education Program Expert based on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH publication 01-3670 Bethesda, MD: National Institute of Health; 1999;
  5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications (Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation). Diabet Med. 1998;15:539–553
  6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  7. Smith SC, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, Ofili E, et al. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation. 2005;111:e134–e139
  8. Meis SB, Schuster D, Gaillard T, Osei K. Metabolic syndrome in nondiabetic, obese, first-degree relatives of African Americans patients with type 2 diabetes: African Americans triglycerides-HDL-C and insulin resistance paradox. Ethn Dis. 2006;16:830–836
  9. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167–174
  10. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–2140
  11. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28:2019–2024
  12. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? (Estimating the progression and cost of the US obesity epidemic). Obesity (Silver Spring). 2008;16:2323–2330
  13. Candib LM. Obesity and diabetes in vulnerable populations: reflection on proximal and distal causes. Ann Fam Med. 2007;5:547–556
  14. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208–2219
  15. Peralta CA, Ziv E, Katz R, Reiner A, Burchard EG, Fried L, et al. African ancestry, socioeconomic status, and kidney function in elderly African Americans: a genetic admixture analysis. J Am Soc Nephrol. 2006;17:3491–3496
  16. Felton GM, Boyd MD, Bartoces MG, Tavakoli AS. Physical activity in young African Americans women. Health Care Women Int. 2002;23:905–918
  17. Ham SA, Yore MM, Kruger J, Heath GW, Moeti R. Physical activity patterns among Latinos in the United States: putting the pieces together. Prev Chronic Dis. 2007;4:A92
  18. Black JL, Macinko J. Neighborhoods and obesity. Nutr Rev. 2008;66:2–20
  19. Pérez-Escamilla R, Putnik P. The role of acculturation in nutrition, lifestyle, and incidence of type 2 diabetes among Latinos. J Nutr. 2007;137:860–870
  20. Slattery ML, Sweeney C, Edwards S, Herrick J, Murtaugh M, Baumgartner K, et al. Physical activity patterns and obesity in Hispanic and non-Hispanic white women. Med Sci Sports Exerc. 2006;38:33–41
  21. Abraído-Lanza AF, Chao MT, Flórez KR. Do healthy behaviors decline with greater acculturation? (Implications for the Latino mortality paradox). Soc Sci Med. 2005;6:1243–1255
  22. Chichlowska KL, Rose KM, Diez-Roux AV, Golden SH, McNeill AM, Heiss G. Individual and neighborhood socioeconomic status characteristics and prevalence of metabolic syndrome: the Atherosclerosis Risk in Communities (ARIC) Study. Psychosom Med. 2008;70:986–992
  23. Caballero AE, Bousquet-Santos K, Robles-Osorio L, Montagnani V, Soodini G, Porramatikul S, et al. Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care. 2008;31:576–582
  24. Falkner B. Insulin resistance in African Americans. Kidney Int. 2003;63:S27–S30
  25. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52:2490–2496
  26. Ferranini E, Gastaldelli A, Matsuda M, Miyazaki Y, Pettiti M, Glass L, et al. Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab. 2003;88:3251–3257
  27. Goran MI, Bergman RN, Cruz ML, Watanabe RM. Insulin resistance and associated compensatory responses in African-American and Hispanic children. Diabetes Care. 2002;25:2184–2190
  28. Patel DA, Srinivasan SR, Xu JH, Li S, Chen W, Berenson GS. Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metabolism. 2006;55:699–705
  29. Caballero AE. Type 2 diabetes in the Hispanic or Latino population: challenges and opportunities. Curr Opin Endocrinol Diabetes Obes. 2007;14:151–157
  30. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992 (National Health and Nutrition Examination Survey). JAMA. 2000;283:2404–2410
  31. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–1551
  32. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med. 1993;234:25–30
  33. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–480
  34. Short RA, Johnson RJ, Tuttle KR. Uric acid predicts cardiovascular disease in the absence of hypertension and independent of diuretic therapy, renal function, and microalbuminuria. J Am Soc Nephrol. 2003;14:676A
  35. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87:1411–1414
  36. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278–1289
  37. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J–17J
  38. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127:321–336
  39. Lara-Castro C, Doud EC, Tapia PC, Munoz AJ, Fernandez JR, Hunter GR, et al. Adiponectin multimers and metabolic syndrome traits: relative adiponectin resistance in African Americans. Obesity (Silver Spring). 2008;16:2616–2623[Epub 2008 Sep 25]
  40. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art?. Am J Physiol Heart Circ Physiol. 2007;292:H1655–H1663
  41. Lee S, Bacha F, Gungor N, Arslanian SA. Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care. 2006;29:51–56
  42. Chen J, Gu D, Chen CS, Hamm LL, Muntner P, Batuman V, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100–1106
  43. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D, et al. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436–2440
  44. Lea J, Cheek D, Thornley-Brown D, Appel L, Agodoa L, Contreras G, et al. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis. 2008;51:732–740
  45. Lucove J, Vupputuri S, Heiss G, North K, Russell M. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study. Am J Kidney Dis. 2008;51:21–28
  46. Navaneethan SD, Yehnert H, Moustarah F, Schreiber M, Shauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565–1574
  47. Navarro-Diaz M, Serra A, Romero R, Bonet J, Bayés B, Homs M, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol. 2006;17:S213–S217
  48. Notwehr F. Attitudes and behaviors related to weight control in two diverse populations. Prev Med. 2008;39:674–680
  49. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169
  50. K/DOQI Clinical Practice Guidelines for managing dyslipidemias in chronic kidney disease. [cited 2008 December 10] http://www.kidney.org/professionals/KDOQI/guidelines_lipids
  51. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews. 2009;Issue 2. Art. No.: CD007784 DOI: 10.1002/14651858.CD007784
  52. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  53. ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) (ALLHAT Collaborative Research Group). JAMA. 2000;283:1967–1975

PII: S0270-9295(09)00174-0

doi: 10.1016/j.semnephrol.2009.10.008

Seminars in Nephrology
Volume 30, Issue 1 , Pages 51-58 , January 2010

Article Tools